Please enter your AHPRA number to access the hub. For any further questions or support, please contact firstname.lastname@example.org or call 1800 288 382.
Lenalidomide (PSH) Training Resources for Patient Safety Hub
Lenalidomide Educational Resources
Patient Safety Hub
The Teva Patient Safety Hub is a digital Pregnancy Prevention Programme*. It enables healthcare professionals to register, initiate patients on treatment, complete and approve Prescription Authorisation Forms. The Programme is commissioned in alignment with the risk minimisation requirements set by the TGA for the prescribing and dispensing of Lenalidomide-Teva.
*The Pregnancy Prevention Programme, which is a condition of the product licence, is designed to ensure that unborn babies are not exposed to lenalidomide to minimise the risk of teratogenicity.
Medical Information Service
Our Medical Information Service can help with enquiries about Teva medicines, devices and services. They can also provide copies of regulatory documents such as Patient Information Leaflets, or Summary of Product Characteristics.
Reporting Adverse Events / Pregnancy
Adverse events and pregnancy should be reported. Reporting forms and information can be found at: https://www.tevapharm.com/teva-medical-information/report-a-side-effect-form/. Adverse events should also be reported to Teva using the online reporting form, or email: Safety.Australia@tevapharm.com.
Tel: 1800 960 819 (AU)
Order Inquiries or to book your training contact your local KAM:
|PBS Information: Authority Required
Refer to PBS Schedule for full authority information
PLEASE REVIEW PRODUCT INFORMATION (PI) BEFORE PRESCRIBING.
Full PI can be accessed at https://rss.medsinfo.com.au/tb/pi.cfm?product=tbplenal10822 or from Medical Information on 1800 AU TEVA (1800 288 382).
Date of preparation: April 2023, LENO-AU-00004